Try our Advanced Search for more refined results

Mallinckrodt plc

Track this case

Case overview

Case Number:

1:20-bk-12522

Court:

Delaware

Nature of Suit:

Firms

Companies

Government Agencies

Sectors & Industries:

  1. December 06, 2021

    Mallinckrodt Escapes $320M Acthar Antitrust Claim In Ch. 11

    A Delaware bankruptcy judge Monday rejected a bid by insurers for a $320 million priority antitrust claim in Mallinckrodt's Chapter 11 case, saying they had failed to show it was the drugmaker and not federal regulators that kept competition to its Acthar gel off the market.

  2. November 29, 2021

    Mallinckrodt Gets Ch. 11 Stay Of Acthar Suits Extended

    A Delaware bankruptcy judge agreed Monday with drugmaker Mallinckrodt PLC that more than a dozen lawsuits against the debtor relating to its marketing of Acthar gel products should be paused for an additional 90 days so that plan confirmation proceedings aren't derailed in the coming weeks.

  3. November 22, 2021

    Judge Rejects Probe Of Asbestos Votes In Mallinckrodt Ch. 11

    A Delaware bankruptcy judge on Monday denied a call for a probe into votes cast for the Mallinckrodt Chapter 11 plan by parties with asbestos claims against the drugmaker, saying the company had met the legal standard for checking the validity of the ballots.

  4. November 19, 2021

    Acthar Claimants Seek Mallinckrodt Chapter 11 Vote Probe

    A group with antitrust claims against Mallinckrodt on Friday asked a Delaware bankruptcy judge to appoint an examiner to investigate what it claims are thousands of questionable votes cast for the drugmaker's Chapter 11 plan on behalf of asbestos injury claimants.

  5. November 18, 2021

    Mallinckrodt Ch. 11 Plan Hearing Won't Restart Monday

    The Delaware bankruptcy judge overseeing Mallinckrodt's Chapter 11 case Thursday granted requests to delay the resumption of the drugmaker's plan confirmation hearing, saying he first needs to digest claims it engaged in drug price manipulation.

  6. November 17, 2021

    Mallinckrodt Denies Manipulating Acthar Market

    Mallinckrodt closed its defense against claims it inflated the price of its Acthar gel on Wednesday, with witnesses saying that the drugmaker didn't suppress a competing product and that the speaking fees it paid to doctors didn't increase sales.

  7. November 16, 2021

    Mallinckrodt Says Insurers' Acthar Claims Off By $317M

    An expert witness for Mallinckrodt told a Delaware bankruptcy judge Tuesday that two insurers seeking more than $317 million in damages wouldn't be owed any more than $2.6 million even if their claims that the drugmaker suppressed competition for its Acthar gel were true.

  8. November 15, 2021

    Mallinckrodt Exec Says Acthar Price Hikes Were Necessary

    A Mallinckrodt executive defended the pricing and marketing of the drugmaker's Acthar gel on Monday as a pair of insurers presented a Delaware judge with the last of their evidence that Mallinckrodt engaged in a yearslong scheme to drive up Acthar's cost.

  9. November 12, 2021

    Insurers Say Mallinckrodt Sales Strategy Cost Them $320M

    A pair of insurers seeking antitrust damages from drugmaker Mallinckrodt over the sales of its Acthar gel put their expert witnesses before a Delaware bankruptcy judge on Friday, claiming they overpaid more than $320 million for Acthar over the past year.

  10. November 08, 2021

    Insurers Claim Mallinckrodt Inflated Acthar Price By $300M

    A pair of health insurers told a Delaware bankruptcy judge Monday that Mallinckrodt PLC owes them more than $300 million because of the drugmaker's alleged efforts to keep a cheaper alternative to its Acthar infantile spasm drug off the market.